These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12920674)

  • 1. [Hormone use in migraine].
    Breckwoldt M
    Dtsch Med Wochenschr; 2003 Aug; 128(33):1731. PubMed ID: 12920674
    [No Abstract]   [Full Text] [Related]  

  • 2. [Postcoital contraception].
    Bergsjo P
    Tidsskr Nor Laegeforen; 1974 Oct; 94(30):2103-4. PubMed ID: 4371625
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives.
    Alsina JC
    Eur J Contracept Reprod Health Care; 2010 Feb; 15(1):1-3. PubMed ID: 20136565
    [No Abstract]   [Full Text] [Related]  

  • 5. [Developmental trends and conformities in the hormone therapy of climacteric disorders].
    Buschbeck H
    Med Klin; 1967 Sep; 62(37):1432-7. PubMed ID: 4298778
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
    Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Migraine patients and oral contraceptives].
    Salvesen R
    Tidsskr Nor Laegeforen; 2000 Jun; 120(16):1883-4. PubMed ID: 10925618
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
    Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.
    Endrikat J; Parke S; Trummer D; Schmidt W; Duijkers I; Klipping C
    Contraception; 2008 Sep; 78(3):218-25. PubMed ID: 18692612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest.
    Wiegratz I; Mittmann K; Dietrich H; Zimmermann T; Kuhl H
    Fertil Steril; 2006 Jun; 85(6):1812-9. PubMed ID: 16759929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrupted quinestrol therapy for inhibition of ovulation: efficacy, duration, and side effects.
    Skerlavay M; Epstein JA
    Int J Fertil; 1967; 12(2):247-50. PubMed ID: 6033904
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ovostat 22, a new oral contraceptive].
    Himmelsbach H
    Med Welt; 1974 Jan; 25(3):106-8. PubMed ID: 4840796
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral contraceptives and heavy periods.
    Drife JO
    Obstet Gynecol; 2011 Apr; 117(4):773-774. PubMed ID: 21422845
    [No Abstract]   [Full Text] [Related]  

  • 14. [Norgestrel and ethinyl estradiol. New oral agent of controlled dosage for regulating fertility].
    Rice-Wray E; Avila C; Gutiérrez J
    Rev Colomb Obstet Ginecol; 1969; 20(2):61-8. PubMed ID: 5803940
    [No Abstract]   [Full Text] [Related]  

  • 15. [1st results with cycle-adapted estrogen-interval therapy for the prevention of migraine].
    Rummel GL
    Med Welt; 1975 Apr; 26(17):838-42. PubMed ID: 1177687
    [No Abstract]   [Full Text] [Related]  

  • 16. Progestins and estrogens and Alzheimer's disease.
    Honjo H; Iwasa K; Kawata M; Fushiki S; Hosoda T; Tatsumi H; Oida N; Mihara M; Hirasugi Y; Yamamoto H; Kikuchi N; Kitawaki J
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):305-8. PubMed ID: 15860274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practitioner's dilemma.
    Jackson JL
    J Reprod Med; 1970 Jul; 5(1):36-7. PubMed ID: 5521769
    [No Abstract]   [Full Text] [Related]  

  • 18. The antiovulatory effect of ethinyl oestradiol in sequential therapy.
    Buus JG; Bang HO; Berthelsen HG
    Dan Med Bull; 1967 Jun; 14(7):161-4. PubMed ID: 6047306
    [No Abstract]   [Full Text] [Related]  

  • 19. [Estrogens and sex hormones--combination preparations. 1].
    Albrecht IH
    Pharm Prax; 1967; 5():98-107. PubMed ID: 4303703
    [No Abstract]   [Full Text] [Related]  

  • 20. [Oral contraceptives, migraine and stroke].
    Næss H; Iversen OE
    Tidsskr Nor Laegeforen; 2013 Mar; 133(6):621-2. PubMed ID: 23552155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.